Small nucleolar RNAs signature (SNORS) identified clinical outcome and prognosis of bladder cancer (BLCA)

Cao, Rui; Ma, Bo; Yuan, Lushun; Wang, Gang; Tian, Ye

doi:10.1186/s12935-020-01393-7

Cited by 7 publications

(6 citation statements)

References 60 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Liu et al used TCGA genome-wide RNA-seq dataset to investigate sarcoma prognostic-related snoRNAs, and identified 15 sarcoma prognostic-related snoRNAs, as well as constructed a sarcoma prognostic signature base on four snoRNAs (24). Cao et al carried out screening for prognostic snoRNAs by using the least absolute and selection operator (LASSO) Cox regression method, and developed a bladder cancer prognostic signature composed of five snoRNAs (25). Both of the above studies confirmed that U3 can be used as a prognostic marker for corresponding tumors (24,25).…”

Section: Discussionmentioning

confidence: 96%

“…carried out screening for prognostic snoRNAs by using the least absolute and selection operator (LASSO) Cox regression method, and developed a bladder cancer prognostic signature composed of five snoRNAs ( 25 ). Both of the above studies confirmed that U3 can be used as a prognostic marker for corresponding tumors ( 24 , 25 ). Similarly, Zhao et al.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma

et al. 2021

View full text Add to dashboard Cite

ObjectiveThe present study used the RNA sequencing (RNA-seq) dataset to identify prognostic snoRNAs and construct a prognostic signature of The Cancer Genome Atla (TCGA) lower grade glioma (LGG) cohort, and comprehensive analysis of this signature.MethodsRNA-seq dataset of 488 patients from TCGA LGG cohort were included in this study. Comprehensive analysis including function enrichment, gene set enrichment analysis (GSEA), immune infiltration, cancer immune microenvironment, and connectivity map (CMap) were used to evaluate the snoRNAs prognostic signature.ResultsWe identified 21 LGG prognostic snoRNAs and constructed a novel eleven-snoRNA prognostic signature for LGG patients. Survival analysis suggests that this signature is an independent prognostic risk factor for LGG, and the prognosis of LGG patients with a high-risk phenotype is poor (adjusted P = 0.003, adjusted hazard ratio = 2.076, 95% confidence interval = 1.290–3.340). GSEA and functional enrichment analysis suggest that this signature may be involved in the following biological processes and signaling pathways: such as cell cycle, Wnt, mitogen-activated protein kinase, janus kinase/signal transducer and activator of tran-ions, T cell receptor, nuclear factor-kappa B signaling pathway. CMap analysis screened out ten targeted therapy drugs for this signature: 15-delta prostaglandin J2, MG-262, vorinostat, 5155877, puromycin, anisomycin, withaferin A, ciclopirox, chloropyrazine and megestrol. We also found that high- and low-risk score phenotypes of LGG patients have significant differences in immune infiltration and cancer immune microenvironment.ConclusionsThe present study identified a novel eleven-snoRNA prognostic signature of LGG and performed a integrative analysis of its molecular mechanisms and relationship with tumor immunity.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 99%

Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 25 Risk score models based on prognostic genes related to metabolism, 26 pyroptosis, 27 and ferroptosis 28 have been established for DLBCL, providing novel ideas for individualized therapeutic strategies in DLBCL patients. The past few years have witnessed the potential of several snoRNAs as prognostic molecular biomarkers in various cancers, and predictive risk signatures based on certain snoRNAs have been found in carcinomas of the lung, 29 , 30 liver, 31 stomach, 32 colon, 33 kidney, 34 , 35 bladder, 36 head and neck, 37 and eyes, 38 as well as sarcoma, 39 and T‐cell lymphoma. 40 The current literature has reported the potential oncogenic functions of several snoRNAs in the carcinogenesis of DLBCL, 16 , 17 , 18 , 19 and SNHG12 might be a risk factor for the clinical outcome of DLBCL patients.…”

Section: Discussionmentioning

confidence: 99%

Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B‐cell lymphoma

Huang

Xie

et al. 2022

Cancer Medicine

View full text Add to dashboard Cite

Background Diffuse large B‐cell lymphoma (DLBCL) is a non‐Hodgkin lymphoma with high mortality rates. Small nucleolar RNAs (snoRNAs) are tumor‐specific biological markers, but there are few studies on the role of snoRNAs in DLBCL. Materials and Methods Survival‐related snoRNAs were selected to construct a specific snoRNA‐based signature via computational analyses (Cox regression and independent prognostic analyses) to predict the prognosis of DLBCL patients. To assist in clinical applications, a nomogram was built by combining the risk model and other independent prognostic factors. Pathway analysis, gene ontology analysis, transcription factor enrichment, protein–protein interactions, and single nucleotide variant analysis were used to explore the potential biological mechanisms of co‐expressed genes. Results Twelve prognosis‐correlated snoRNAs were selected from the DLBCL patient cohort of microarray profiles, and a three‐snoRNA signature consisting of SNORD1A, SNORA60, and SNORA66 was constructed. DLBCL patients could be divided into high‐risk and low‐risk cohorts using the risk model, and the high‐risk group and activated B cell‐like (ABC) type DLBCL were linked with disappointing survival. In addition, SNORD1A co‐expressed genes were inseparably linked to the biological functions of the ribosome and mitochondria. Potential transcriptional regulatory networks have also been identified. MYC and RPL10A were the most mutated SNORD1A co‐expressed genes in DLBCL. Conclusion Put together, our findings explored the potential biological effects of snoRNAs in DLBCL, and provided a new predictor for DLBCL prediction.

show abstract

“…Bladder cancer (BC) is the most common malignant tumor of the urinary tract (47). About 70% of patients diagnosed with bladder cancer have non-muscle-infiltrating BC, with the remaining 25-30% having myometrial-infiltrating BC.…”

Section: Txnip and Bladder Cancermentioning

confidence: 99%

Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers

et al. 2020

View full text Add to dashboard Cite

Thioredoxin-interacting protein (TXNIP) is a thioredoxin-binding protein that can mediate oxidative stress, inhibit cell proliferation, and induce apoptosis by inhibiting the function of the thioredoxin system. TXNIP is important because of its wide range of functions in cardiovascular diseases, neurodegenerative diseases, cancer, diabetes, and other diseases. Increasing evidence has shown that TXNIP expression is low in tumors and that it may act as a tumor suppressor in various cancer types such as hepatocarcinoma, breast cancer, and lung cancer. TXNIP is known to inhibit the proliferation of breast cancer cells by affecting metabolic reprogramming and can affect the invasion and migration of breast cancer cells through the TXNIP-HIF1α-TWIST signaling axis. TXNIP can also prevent the occurrence of bladder cancer by inhibiting the activation of ERK, which inhibits apoptosis in bladder cancer cells. In this review, we find that TXNIP can be regulated by binding to transcription factors or other binding proteins and can also be downregulated by epigenetic changes or miRNA. In addition, we also summarize emerging insights on TXNIP expression and its functional role in different kinds of cancers, as well as clarify its participation in metabolic reprogramming and oxidative stress in cancer cells, wherein it acts as a putative tumor suppressor gene to inhibit the proliferation, invasion, and migration of different tumor cells as well as promote apoptosis in these cells. TXNIP may therefore be of basic and clinical significance for finding novel molecular targets that can facilitate the diagnosis and treatment of malignant tumors.

show abstract

Small nucleolar RNAs signature (SNORS) identified clinical outcome and prognosis of bladder cancer (BLCA)

Cited by 7 publications

References 60 publications

Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma

Integrative Analysis of a Novel Eleven-Small Nucleolar RNA Prognostic Signature in Patients With Lower Grade Glioma

Identification of three small nucleolar RNAs (snoRNAs) as potential prognostic markers in diffuse large B‐cell lymphoma

Research Progress of TXNIP as a Tumor Suppressor Gene Participating in the Metabolic Reprogramming and Oxidative Stress of Cancer Cells in Various Cancers

Contact Info

Product

Resources

About